NCT06656559View on ClinicalTrials.gov

Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

August 31, 2026

Conditions
Unresectable Biliary Tract Carcinoma
Interventions
DRUG

Envafolimab and Surufatinib

Envafolimab: 150mg, SC, qw Surufatinib: 150mg, p.o., qd

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06656559 - Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | Biotech Hunter | Biotech Hunter